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ABSTRACT

STATISTICAL METHODS FOR THE ANALYSIS AND DEVELOPMENT OF QUANTITATIVE
IMAGING BIOMARKERS
Carolyn E. Lou
Russell T. Shinohara
The field of neuroimaging statistics is concerned with elucidating meaningful conclusions from
high-dimensional imaging objects, often in the form of single-dimensioned summary statistics.
Ideally, these summaries should provide interpretable biomarker measurements that can guide
patient diagnoses or treatment decisions while minimizing information loss associated with
dimension reduction. This dissertation is focused on (1) exploring methods for analyzing
previously developed imaging biomarkers and (2) developing new imaging biomarkers using both
well-established and novel imaging analysis techniques. We approach this problem in three ways:
in our first project, we assess how previously developed imaging biomarkers can best be
incorporated into downstream analyses in the context of a clinical trial. This work conceptualizes
imaging biomarkers as measurements which intrinsically contain historical information on a
patient and examines the effect of incorporating these predictors on the statistical power in a
clinical trial analysis. For our second project, we develop a radiomic predictor that automatically
identifies an important prognostic biomarker in multiple sclerosis, relying on quantification of
imaging patterns potentially associated with brain atrophy and more severe disease courses. In
our third project, we construct a coordinate system and framework for multiple sclerosis lesions
analyses for more sensitive and specific biomarker development. We use dimension reduction
and flexible nonparametric modelling to assess the diagnostic value of this method. These
methods lay the groundwork for improving future work developing and utilizing imaging
biomarkers with imaging statistics.
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CHAPTER 1:
INTRODUCTION

Neuroimaging data are more accessible and easily collected than ever, with heavy financial
support from federal governments leading to an abundance of data in the form of brain images to
be analyzed (Sporns, Tononi and Kötter, 2005; Insel, Landis and Collins, 2013; Jiang, 2013;
Amunts, 2014). Despite growing access to computational resources, the complex nature of these
data makes it difficult to draw conclusions from unprocessed images. Occasionally, large studies
have resulted in spurious connections that have not held up under further scrutiny (Eklund,
Nichols and Knutsson, 2016; Cremers, Wager and Yarkoni, 2017; Vandekar and Stephens,
2021). Statistical analyses using these data must be conducted carefully to avoid such results.
Tools which can summarize large imaging data into a single-dimensioned, easily-interpretable
metrics can aid in improving our ability to ascertain clinical insights and understand neurological
phenomena.
In this dissertation, we aim to assess the utility and development of these single-dimensioned
metrics, which we call radiomic predictors or imaging biomarkers. We first explore how
incorporating imaging biomarkers into current and future clinical trial studies may be used to
enhance their statistical power. Additionally, we develop novel imaging biomarkers that can be
used to summarize complex imaging patterns present in magnetic resonance images (MRI) of
multiple sclerosis (MS) lesions. These resulting biomarkers could potentially be used as a clinical
tool in future clinical trials.
Traditional methods for estimating sample size requirements in a clinical trial rely on group mean
data and population average treatment effects (Donner, 1984; Kirby, Gebski and Keech). Many
historical control methods rely on group-level analyses such as pooling or Bayesian modelling
(Viele et al., 2014). In Chapter 2, we introduce the concept of using individualized evaluation of
treatment effects with neuroimaging biomarkers and provide a framework for practically
1

incorporating this approach into future clinical trials of neurologic disease when baseline imaging
is available (Lou et al., 2021a). We show that machine learning tools can provide individualized
predictions for patients under study, which in turn can be used to inform sample size calculations
with individualized estimates of clinical outcome in a trial. This methodology can substantially
improve statistical power for detecting a treatment effect.
In Chapters 3 and 4, we shift our focus to development of imaging biomarkers that quantify
potentially important prognostic and diagnostic imaging signals in MS lesions. As a demyelinating
and inflammatory disorder, MS often manifests with lesions in the brain and spinal cord that can
be detected in vivo with MRI (Sahraian and Radü, 2007). Imaging biomarkers such as total lesion
volume and lesion count are commonly used both for diagnosis and for tracking disease
progression, though recent studies suggest that misdiagnosis of MS is not uncommon, potentially
due to the non-specificity of white-matter lesion presentation (Solomon et al., 2016; Thompson et
al., 2018; Gaitán and Correale, 2019). New imaging signals such as the central vein sign and the
paramagnetic rim signal provide possible avenues down which to more specifically characterize
MS lesions while potentially assessing prognosis as well (Sati et al., 2016; Absinta et al., 2019;
Maggi et al., 2020b).
In Chapter 3, we develop an automated tool for quantification of the paramagnetic rim signal,
most notably shown be associated with greater disease burden and more severe tissue damage
(Absinta et al., 2016; Tozlu et al., 2021). Manual inspection of MS lesion for the presence of a
paramagnetic rim is time consuming and prone to inter- and intra-rater variability. We propose an
automated method for identifying PRLs that would improve efficiency of study and facilitate
translation of this biomarker into larger research studies and clinical practice. We use highdimensional radiomic feature extraction along with a random forest classification model, which
can flexibly model high dimensional data, to identify PRLs.
In Chapter 4, we develop our own method for quantifying imaging patterns. Quantitative radiomic
analysis is a powerful tool for the analysis of focal MRI lesions but does not typically incorporate
2

the spatial location of nor spatial patterns within a lesion. We leverage detection of known
imaging biomarkers and estimation of sublesions with multimodal imaging, particularly relevant in
the context of confluent clusters of lesions, to define a common coordinate system for all white
matter lesions. We use dimension reduction to then assess the added value of our method by
examining association with clinical outcomes.

3

CHAPTER 2:
LEVERAGING MACHINE LEARNING IMAGING BIOMARKERS TO AUGMENT
STATISTICAL POWER IN CLINICAL TRIALS

2.1. Introduction
The power of a clinical trial is the probability of detecting a statistically significant difference
between treatment groups under a set of assumptions. Power increases as the magnitude of the
true difference in outcomes between treatment groups increases, as the accuracy of
measurement for the outcome measure increases, and as sample size increases (Faul et al.,
2007). When a treatment effect exists, failure to detect a statistically significant difference
between treatment groups can occur as the result of a myriad of reasons, including small
treatment effect, poor measurement of the primary outcome, inadequate sample size
(underpowered studies), or treatment effect heterogeneity (Wittes, 2002; Anderson et al., 2017;
Kent et al., 2019; Rekkas et al., 2020). Failure is more likely in studies of relatively rare neurologic
diseases including glioblastoma multiforme (GBM) because enrolling large samples is difficult, but
failure also occurs in more common diseases with substantial biological heterogeneity and
unstable outcome measures, such as Alzheimer’s disease (Cummings, 2018; McGranahan et al.,
2019; Oxford, Stewart and Rohn, 2020).
Despite many long and expensive trials, no disease modifying drug for Alzheimer’s disease has
been approved (Petersen et al., 2010). Phase III trials for GBM have been more successful, but
treatment efficacy has been modest, with an improvement in median survival of only 7 months
(8‒15 months) for patients in the treatment arms in 44 different trials (Anderson et al., 2008;
Menze et al., 2015). Similar explanations have been proposed for the failure of trials of these two
diseases, including biological heterogeneity, selection of ineffective treatments based on
incomplete understanding of disease biology, starting treatment too late in disease development,
incorrect drug doses, and unreliability of the primary outcome measurements (Davatzikos et al.,
4

2011; Shaffer et al., 2013). All of these explanations may contribute to a reduction in the
magnitude of the treatment effect. If the expected treatment benefit is overestimated, the study
will be underpowered.
Traditionally, trials rely on empirical data from previously conducted studies (often phase II trials,
if available) to estimate sample size requirements to achieve a particular level of power (i.e., 80%,
90%). These traditional methods for estimating sample size requirements rely on group mean
data and calculating sample size requirements based on population average treatment effects.
When historical control data are used, statisticians use methods such as pooling or Bayesian
modeling, which also rely on group-level analyses (Pocock, 1976; Viele et al., 2014). Newer highdimensional predictors such as neuroimaging or genomic data offer the opportunity to include
individualized predictions. This allows for a more precise evaluation of the treatment effect for
each person through comparison of their observed outcome with their predicted outcome, rather
than relying on a group-level effect that determines average outcome. Because of this more
precise evaluation, the residual variance decreases and thus the power to detect this treatment
effect increases.
In this study, we introduce the concept of using individualized evaluation of treatment effects with
neuroimaging biomarkers and provide a framework for practically incorporating this approach into
future clinical trials of neurologic disease when baseline imaging is available. We show that
machine learning tools can provide individualized predictions for patients with Alzheimer’s
disease and GBM, which in turn can be used to inform sample size calculations with
individualized estimates of clinical outcome in a trial. This methodology can substantially improve
statistical power for detecting treatment effects, or alternatively, reduce the sample size needed
to achieve the same power in a clinical trial.

5

2.2. Materials and methods
Our method relies on access to two sets of data: i) a current clinical trial designed to study an
outcome of interest and ii) a previously observed cohort of similar subjects treated according to
the current standard of care with data on the outcome of interest. We narrow our focus in this
work to imaging biomarkers and associated studies, so we assume that imaging data has been
gathered at study enrollment for both sets of trials. In both of our disease applications, imaging
data are regularly obtained through standard course of care, either for exclusion of other
pathologies or for diagnosis itself. The techniques proposed here are also directly applicable to
other -omic modeling scenarios, and generally, to any predictive marker of standard of care
outcome.
We aim to show that previously developed and validated radiomic prediction models, which
summarize imaging patterns that predict future clinical outcomes of interest, can in some cases
result in improved statistical power for detecting treatment effect (Fig. 1). These outcomes of
interest can be endpoints such as response to treatment, patient survival, or progression-free
survival. The model, which is built based on a historical cohort, can then be used in conjunction
with data collected from the current trial to generate individualized values of the radiomic score
for each of the current participants. These individualized scores represent predicted values for the
outcomes of the treated individuals in the current trial had they instead been assigned to the
control group. The incorporation of these predicted values as a covariate in the final analysis of
the current trial lends power to the detection of the effect of a treatment by modeling the intersubject variability in the outcome in terms of baseline heterogeneity represented in the baseline
imaging.
In practice, this could be done by using a model developed for a previously validated radiomic
predictor, applying it to data from a current trial of interest, and then incorporating the newly
derived values of that radiomic predictor as a covariate in the study analysis. This would reduce
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uncertainty in the estimate of the overall treatment effect and therefore increase statistical power
to detect a treatment effect.

Figure 2.1: Method Visualization and Description. A: Workflow for implementing the proposed method in
a new clinical trial. B (continuous) and C (survival outcome): Schematic diagram for individualized
predictions that are generated for each person in the current trial, where the solid red lines indicate observed
outcome for the participants of the current trial and the dashed blue lines indicate predicted outcome for
those participants had they not been treated. Fig. 1B illustrates the method for continuous outcomes, where
the left side represents the outcomes of those randomized to the control arm and the right side represents
the outcomes of treated participants. The predicted outcome values (dashed blue lines) for the control units
had they not been treated would be exactly what they are observed to be (solid red lines), while the
predicted outcome values (dashed blue lines) for the treated units had they not been treated are different
from the observed outcome (solid red lines). Fig. 1C illustrates the analogous mechanism for survival
outcomes, where the predicted survival times for the control units (dashed blue lines) are the same as the
observed survival times (solid red lines), whereas the predicted survival for the treated individuals are lower
than the observed survival times. Our method capitalizes on these differences to augment statistical power.

To investigate the advantage of this approach, we implemented our models in two scenarios
motivated by two different disease areas (GBM and AD). To better approximate real-life clinical
trial performance, we use radiomic and outcome data from two observational studies to generate
hypothetical study data, where the first focuses on the continuous outcomes of cognitive decline
in prodromal Alzheimer’s disease and the second on the survival after diagnosis with GBM. With
these studies, we performed plasmode simulations, where we randomly split our observational
data into a theoretical historical cohort and a theoretical trial cohort. We then simulate effects in a
randomly selected subset, corresponding to one arm, of the trial cohort. We then compare the
statistical power of our proposed approach with the classical modeling approach that does not
include radiomic prediction-based modeling.
7

We also performed simulations with fully synthetic data, where the populations were generated to
be homogeneous except for random error and treatment status. Code for both the synthetic data
simulations and plasmode simulations are available on our GitHub
(https://github.com/carolynlou/hcct).

2.2.1. Data
For our analyses, we relied only on observational data. These data were obtained from ADNI and
the University of Pennsylvania for our AD and GBM studies respectively (Petersen et al., 2010;
Macyszyn et al., 2016). There was no missingness in either of the two datasets, and no patients
dropped out before baseline imaging data could be collected. Our studies of performance in a
clinical trial setting were based on plasmode simulations, where we artificially generated
hypothetical trial data from our observational data.
In our first case study, we focused on therapeutic trials for prevention of AD, in which the primary
outcome is typically longitudinal cognitive change. Here, we simplified this outcome and
quantified cognitive change as the difference between memory score measured 2 years from
baseline and memory score measured at baseline. We used a predictive model, called the
SPARE-AD score, which has been previously derived from the Alzheimer's Disease
Neuroimaging Initiative (ADNI, adni.loni.usc.edu) on 283 subjects with mild cognitive impairment
(MCI) who underwent serial MRIs at 1.5T (Davatzikos et al., 2009; Petersen et al., 2010). The
ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael
W. Weiner, MD. For up-to-date information, see www.adni-info.org.
SPARE-AD is derived from patterns of regional brain atrophy (volume loss) captured by atlas
warping methods and high-dimensional pattern classification using support vector machines
(SVM) aiming to differentiate cognitively normal (CN) and Alzheimer’s disease subjects (Fan et
al., 2008; Davatzikos et al., 2009; Da et al., 2013). We used cognitive decline as our outcome
here, as measured by 2-year change from baseline values of the ADNI composite memory score
ADNI-MEM (Crane et al., 2012). Average 2-year change from baseline for ADNI-MEM in the
8

current study was -0.17 (standard deviation 0.49). The average age of the participants was 74.8
years (sd = 7.32), and 99 (35%) of participants were female. A more detailed description of
demographics and clinical characteristics of patients has been published previously (Da et al.,
2013). We note that both the outcome and the disease status of the subjects studied here differ
from the outcome and disease statuses that were used to build SPARE-AD. As a complementary
analysis, we also examined conversion from mild cognitive impairment (MCI) to Alzheimer’s
disease as an outcome, employing time-to-event analysis methods, where we again used the
SPARE-AD score as a radiomic predictor of interest. Approximately 60% of observations were
censored.
As a second case study, we focused on trials for GBM therapies in which the primary outcome is
overall survival time after diagnosis. We analyzed previously collected, anonymized data from
134 patients who were treated for newly diagnosed GBM at the Hospital of the University of
Pennsylvania between 2006 and 2013. The median survival in this sample was 12 months, and
survival data were assessed for all subjects with no loss to follow-up. The average age of patients
in this study was 62.1 years (sd = 12.1), and 53 patients (40%) were female. Detailed
demographics and a clinical description of these subjects have been previously published
(Macyszyn et al., 2016). All people with access to the data were on an institutional IRB. For this
second case study, we investigated the use of cross-validated predictions of survival time based
on radiomic analyses of pre- and post-contrast T1-weighted, T2-weighted and T2- fluid
attenuated inversion recovery (T2-FLAIR), diffusion, and perfusion MRI acquired pre-operatively
at diagnosis. This GBM predictive model utilized an SVM model to differentiate short, medium,
and long survival (Macyszyn et al., 2016).

2.2.2. Statistical Methods
All hypothesis testing was conducted assuming a 5% type 1 error rate and using two-sided
alternatives. In lieu of data from a clinical trial, to explore the utility of our method, we employed
plasmode simulation studies, in which all of our analyses were performed with datasets derived
9

from ADNI and our GBM cohort, but we artificially generated treatment status and treatment
effect. We also explored the method with synthetic data simulations (Fig. 3), in which we
artificially generated a theoretical radiomic predictor, a binary treatment indicator, and an
outcome.
Alzheimer’s Disease Study. For our Alzheimer’s disease plasmode simulation study, we used a
continuous outcome and analyzed our data with linear regression. To compare our method to a
more classical analysis, we fit the following two models, where Equation (1) represents our
method and Equation (2) represents a classical analysis:
=

1
2

+
=

+
+

+
+

Here, Y represents cognitive decline, defined as the difference between ADNI-MEM score
observed at 2 years after baseline and ADNI-MEM score observed at baseline.
radiomic predictor,
parameters

and

represents the treatment indicator, and
are estimated from the data while

represents the

represents random error. The

is added in artificially, as described

below. We note that these models are equivalent to ANOVA-CHANGE models as described in
O’Connell et al (O’Connell et al., 2017).
To conduct the simulation, we randomly split our data into two equal portions, one representing
the source of a treated population and one representing the source of a control population. We
then generated a sample treated arm and a sample control arm that we used for downstream
analysis by sampling with replacement from the respective source samples. For the first group,
indexed by = 1, … , , we set our treatment indicator
as well as the value of the radiomic predictor

= 0 and record the observed outcome ,

at baseline. For the second group, indexed by =

+ 1, … , , we introduced a treatment effect , set our treatment indicator
record outcome

and baseline radiomic predictor measurement

= 1, and again

.

We repeated this process 1000 times, recording the p-value corresponding to the test for
treatment effect each time. We calculated type 1 error rate and power as the percentage of times
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the treatment effect was significant at the

= 0.05 level, where

is set to 0 to assess type 1 error

and a non-zero value to assess power. In order to quantify the sample size benefits from using
this method, we repeated the above procedure for a range of sample sizes
smallest

and recorded the

for which power reached 80%. We explored this for a range of hypothetical effect

sizes, which was defined as

divided by the standard deviation of the outcome .

We also performed a similar analysis with a time-to-event outcome, studying the time to
conversion from MCI to Alzheimer’s disease measured in months. We analyzed this outcome with
the following accelerated failure time models, assuming a log-logistic distribution:
1

= log
2

Here,

=

= log

+
=

represents the radiomic predictor, and

+

+
+

+

represents the binary treatment indicator. We

introduce a multiplicative treatment effect on observed survival or censoring time in the treatment
group and refer to this multiplier as the effect size. In order to mimic a 3-year clinical trial, we
introduce end-of-study censoring at 36 months. We conducted the simulation study as described
previously, assessing sample size benefits as the minimum number of participants for the study.
Glioblastoma Multiforme Study. For our GBM plasmode simulation, we used survival outcomes
and we assessed differences between treatment groups with and without adjustment for the
radiomic prediction by assuming an accelerated failure time model. Specifically, we fit the
following models:
1

= log
2

Here,

is log

, where

=

= log

+
=

+
+

+
+

represents the time to event,

represents the treatment indicator, and

represents the radiomic predictor,

represents random error. In this study, we modelled

using a log-logistic accelerated failure time model. We introduce a treatment effect and conduct
the simulation study for this setting as described previously.
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Synthetic Data Simulation Study. We start by discussing the continuous outcome case. We
simulated data according to the following parametric form:
0.25) denotes a continuous predictor,
"

= 1 = 0.5, and

treatment effect of

=2+4

+

+

~N(0,

, where

is a binary treatment indicator simulated at random with

~# 0,1 is a random error term for = 1, … , . We then introduced a
for these subjects and assessed the significance of the treatment effect with

a Wald test via linear regression. We repeated this process 1000 times, recording the p-value
corresponding to the test for treatment effect each time. We calculated type 1 error and power as
the percentage of iterations in which the treatment effect was significant at the
where we set

= 0.05 level,

to 0 to assess type 1 error and a non-zero value to assess power. In order to

quantify the sample size benefits from using this method, we repeated the above procedure for a
range of sample sizes , corresponding to the total trial size, and recorded the smallest

for

which power reaches 80%. We explored this for a range of hypothetical effect sizes, which we
defined here as

divided by the standard deviation of the outcome.

For the time-to-event outcome case, we followed a similar procedure. Here, the outcome
simulated according to a Weibull distribution such that
represents the time to event,

= log

= 0.5 + 0.25

~ # 0, 1 denotes a continuous predictor, and

was

+ 4 , where
is a random

error term following an extreme value distribution with scale parameter of 4 for = 1, … , , with
total trial size . Then, we introduced a treatment effect of
then used an accelerated failure time model to regress

with probability "

= 1 = 0.5. We

against , testing for the treatment

effect with a Wald test. We introduced end-of-study censoring at 36 months to mimic a 3-year
clinical trial. We assessed power, type 1 error, and sample size benefits as in the continuous
outcome case.

2.2.3. Data availability
The Alzheimer’s disease data used for this study are publicly available and were obtained from
the ADNI database (http://adni.loni.ucla.edu/). Data collected for this study was approved under
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institutional review board protocol #825722 sponsored by the National Institutes of Health. The
GBM data have been uploaded to TCIA, and should be available to the public shortly. For the
purposes of the review process, the data are available as Supporting Information. Data for this
study was collected under institutional review board-approved protocol #706564 sponsored by
the National Institutes of Health.

2.3 Results
For both continuous and time-to-event outcomes, the proposed method consistently reduced the
minimum required sample size

for a given level of power in clinical trial analyses (Fig. 2). In the

Alzheimer’s disease plasmode simulations, where the outcome of interest is cognitive decline,
with an effect size of 0.35, the total required sample size was 246 for the conventional analysis
and 212 with the proposed historical control analysis. As the effect size increased, sample size
requirements decreased for both approaches but decreased more rapidly for the conventional
approach. In the GBM plasmode simulations, where the outcome of interest was survival time, at
an effect size of 1.65, the total required sample size was 128 with the conventional analysis and
74 with the proposed historical control analysis.
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Figure 2.2: Plasmode simulation results. Results from simulated studies under two scenarios. With the
addition of historical controls, the minimum required sample size for 80% power is markedly lower than
using classical two-sample clinical trial analysis. These figures show minimum sample size (vertical axes)
required to achieve 80% power for a range of effect sizes (horizontal axes) based on observed outcome and
radiomic predictions. Fig. 2A shows the results from simulations for continuous outcome measures of
cognition in our Alzheimer’s cohort from ADNI, analyzed using a linear regression model with and without
incorporation of the radiomic predictor (left). Fig. 2B shows the results from simulations for survival in our
glioblastoma cohort, comprised of 134 patients who were treated for newly diagnosed GBM at the Hospital
of the University of Pennsylvania between 2006 and 2013 and analyzed with an accelerated failure time
model with and without incorporation of the radiomic predictor. Note that the proposed method that
leverages historical controls to build radiomic predictions (red) requires lower samples sizes than the
classical approach (blue). Minimum required sample size was calculated as the smallest sample size that
achieved 80% power as calculated by the percentage of Monte Carlo simulations with a non-zero treatment
effect that were significant at the =0.05 level.

Reductions in sample size requirements were greater for smaller effect sizes, so the benefit of
historical controls declined as effect size increased. Type 1 error remained controlled throughout
all experiments conducted. In the Alzheimer’s disease study with a continuous outcome, our
proposed method resulted in a 14-16% decrease in the minimum required sample size. In the
GBM study, our method reduced the required sample size by as much as 48%. Our simulations
with fully synthetic data supported these findings.
Table 2.1 summarizes the effect of using our method on sample size across a range of power
levels and effect sizes.
Table 2.1: Minimum Required Sample Size for Different Powers and Effect Sizes. We provide the
minimum required sample size for both 80% and 90% power across a range of effect sizes in both our ADNI
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cohort and our cohort of patients with glioblastoma multiforme (GBM). For our ADNI dataset, because the
radiomic predictor of interest is known to be an accurate predictor of MCI to Alzheimer’s disease conversion
time, we also explored the utility of incorporating this method into a survival analysis.
Minimum Sample Size
CohortWithout
Power
Effect Size
With Historical
Outcome
Historical
Controls
Controls
ADNI0.8
0.40
174
200
Continuous

0.9

ADNI-Survival

0.8

0.9

GBM-Survival

0.8

0.9

0.46

146

170

0.61

74

88

0.40

228

263

0.46

172

204

0.61

97

112

1.7

242

287

1.8

206

254

1.9

180

219

1.7

—

—

1.8

271

332

1.9

238

292

1.8

56

98

1.9

44

82

2

38

70

1.8

74

130

1.9

60

108

2

50

90

We also explored our method with synthetic data simulations. Results for these simulations were
similar to those from the plasmode simulation studies. With the synthetic data simulations, we
noticed even greater sample size gains with the use of our proposed methodology. In settings
with continuous outcomes, at the smallest effect size that we studied of 0.4, the total required
sample size was 380 when using the conventional analysis and 230 when properly incorporating
information from historical controls. As in the plasmode studies, this reduction became less
pronounced as the effect size increased. This is partly due to a more rapid decrease in required
sample size under the conventional approach than for the proposed method. In the time-to-event
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outcome simulations, at the smallest effect size studied of 1.1, the total required sample size was
540 with the conventional analysis and 310 with the proposed historical control analysis.

Figure 2.3: Synthetic data simulation results. Results from simulated studies with synthetic data
generated to be homogenous across all cohorts except for random error and treatment status. These figures
show the minimum sample size required to achieve 80% power for a range of effect sizes, where minimum
sample size was calculated as the smallest sample size for which at least 80% of Monte Carlo simulations
with a non-zero treatment effect were significant at the =0.05 level. Fig. 3A shows the results for
simulations with a continuous outcome, analyzed using linear regression with and without incorporation of
the radiomic predictor, and Fig. 3B shows the results for simulations with a survival outcome, analyzed using
an accelerated failure time model with and without incorporation of the radiomic predictor. In both cases, the
proposed method that leverages historical controls in the form of radiomic predictions (red) requires lower
sample sizes than the classical approach (blue).

2.4. Discussion
We have shown that individualized machine-learning-based imaging biomarkers can be useful
tools in clinical trial analyses when the necessary information is available, offering decreased
sample size requirements for a given effect size. The novelty of this method arises from the
incorporation of individualized predictions based on powerful predictive algorithms which lend
power to the detection of an average treatment effect due to targeting of the individuals in a given
clinical trial. As robust neuroimaging biomarkers derived via machine learning models become
more available, the historical datasets that can be analyzed with those models grow in size.
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These changes are expected to strengthen the radiomic prediction models like the ones used in
this study.
Our incorporation of the radiomic predictor relies on the existence of previously developed
imaging biomarkers, which for the purposes of this paper, we theorize as having been trained on
a historical cohort. Because the radiomic predictor has been previously trained on a historical
cohort, the models that we fit to analyze a current trial inherently incorporate information from
historical controls. When we do not include the radiomic predictor into the clinical trial analysis,
we do not incorporate information from historical controls. We generate values of the radiomic
predictor for the current sample using the model that was developed with a previous cohort. For
our simulations, we assume that the current trial is being run on an experimental drug and the
goal is to show superiority (O’Connell et al., 2017). Patients enrolled in a clinical trial or a cohort
study may not be representative of patients in a population of interest. Differences between these
populations are the result of the explicit inclusion/exclusion criteria of a clinical trial as well as the
indirect differences between patients who are willing to volunteer for a clinical trial and those who
are not (Jordan et al., 2013). Event rates can also be higher in a cohort study than in a clinical
trial, potentially due to these same biases. However, randomization of the current trial participants
ensures that even if the historical control population is different from the trial population in
important ways we would not realize inflated type 1 error. The differences may however impact
the predictive performance of the radiomic predictor for the outcome of interest, which could thus
impact statistical power of the proposed methodology and attenuate the sample size benefits.
In the event that a primary analysis of an endpoint does not yield statistically significant results,
this technique could potentially be used in a sensitivity analysis to aid interpretation. Performance
of a secondary analysis looking to draw conclusions about the efficacy of a treatment could result
in increases of type 1 error and thus spurious decisions, but incorporation of this technique into
an exploratory analysis aimed at characterizing the impact of baseline heterogeneity on inference
could illuminate important phenomena that would otherwise be missed.
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We note that unexplained biological heterogeneity among the cohorts under study may have
attenuated the power gains that were observed. To assess the potential gains of using this
method in cases where the degree of biological heterogeneity explained was modifiable, we
conducted simulation studies with data generated so as to be homogenous except for random
error and treatment status (Fig. 3). In that setting, power gains and subsequent sample size
reductions were much more dramatic.
Here, we used two previously developed biomarkers, one of which was trained to classify an
outcome different from the target of the clinical trial analysis, and the other of which was trained
to classify the same outcome as the clinical trial analysis. While both predictors offered gains in
sample size reduction, the predictor built specifically for the outcome of interest in the clinical trial
performed better and offered more substantial gains. We expect that the gains in power will likely
be larger when the model is trained to predict the primary outcome of the clinical trial, though this
needs to be empirically tested across a range of applications.
This approach is not limited to imaging biomarkers. It can be applied to a broad array of factors
associated with the outcomes of interest in a clinical trial, such as clinical variables, blood or
cerebrospinal fluid-based biomarkers, or genomic markers. The choice between use of
biomarker-only prediction models as opposed to clinical and biomarker prediction models can be
decided on a case-by-case basis, depending on the hypothesis of interest in a given study. In
general, the more robust the associations among the predictors and the outcome of interest, the
greater the anticipated gains in power or reduction in sample size required for a specified level of
power.
The approach proposed in this paper has some limitations. First, the use of radiomic predictions
can be hindered by the cost of collecting imaging data (Fleiss, 2011). Though many modern
clinical trials of neurologic disease now incorporate baseline MR imaging into their protocol
(Hammoud et al., 1996; Perry et al., 2017; Honig et al., 2018; Herrlinger et al., 2019; Egan et al.,
2019; Wirsching et al., 2021; Mintun et al., 2021), especially in those of AD and GBM, which we
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use as examples in this manuscript, imaging remains expensive and potentially extraneous for
the study of certain diseases. This method is only helpful when baseline imaging is available, and
in the absence of baseline imaging for participants of a new study, incorporation of imaging
biomarkers through prior scans from unknown length of time prior to the new study may result in
attenuated benefits of statistical power and imperfect characterization of disease load. This can
also impact the accuracy of the sample size calculation in that incorporation of data that does not
reflect true baseline heterogeneity at the beginning of a new study can increase uncertainty in the
analysis.
Furthermore, reductions in sample size requirement depend upon the strength of the prediction
model. In the current study, both imaging biomarkers considered were built based on SVMs, but
other machine learning techniques such as deep convolutional neural networks may provide
more predictive power (Davatzikos, 2019). In addition, gains in power for the primary outcome will
be associated with gains in power for secondary outcomes only to the extent that predictions from
the prediction model are associated with the secondary outcomes. This will likely be determined
by the degree of correlation between the primary outcomes and a set of secondary outcomes. In
principle, within a single trial, separate prediction models could be developed for two or more coprimary endpoints. Incorporation of this method into randomized trials with more complex
designs, such as one incorporating stratification by confounders or a one-arm trial, requires
further statistical research.
Finally, if a radiomic predictor is trained on data sampled from a different population than that
which is studied in the current trial, the improvements in statistical power may be less
pronounced. However, due to the randomization in the study, the type 1 error rate is expected to
be maintained and internal validation or calibration of the predictive model is possible using data
from the control arm of a clinical trial.
The key conclusion arising from our study is that machine-learning-based predictive models can
be used to effectively improve the statistical power of clinical trials by leveraging the wealth of
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information available in neuroimaging data to generate personalized predictions of outcome.
Imaging biomarkers are seldom incorporated into clinical trial analyses, but we have
demonstrated that when the necessary information is available, they can be a powerful tool,
especially when evaluating therapies for rare diseases such as GBM or heterogenous diseases
with long and slow progressions that require many years of patient follow-up such as AD.
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CHAPTER 3:
AUTOMATED DETECTION OF PARAMAGNETIC RIM LESIONS IN MULTIPLE
SCLEROSIS

3.1. Introduction
Multiple sclerosis is a demyelinating and inflammatory disorder whose hallmark is lesions in the
brain and spinal cord (Sahraian and Radü, 2007). These lesions can be detected in vivo with MRI
and are often quantified as total lesion volume and lesion count, both of which can be used as
measures of disease burden and to track disease progression (Popescu et al., 2013). Imaging
biomarkers such as these are commonly used in the clinic and as surrogate endpoints in clinical
trials (Filippi and Agosta, 2010; Sormani and Bruzzi, 2013). However, other known biological
processes of MS are left uncaptured.
Chronic active lesions, a subset of MS lesions that are more prevalent in patients with more
severe disease (Frischer et al., 2015; Luchetti et al., 2018; Absinta et al., 2019), have imaging
and histopathology findings suggestive of ongoing tissue damage (Absinta et al., 2016; DalBianco et al., 2017; Kaunzner et al., 2019; Gillen et al., 2021) and have until recently only been
detectable by histopathology. These lesions have also been termed as slowly expanding, or
smoldering lesions. At an estimated prevalence of as low as 4% but up to 10-15% of all MS
lesions, this type of lesion is sufficiently common and deleterious to warrant considerable efforts
for biomarker development (Frischer et al., 2015; Absinta et al., 2016; Dal-Bianco et al., 2017;
Chawla et al., 2018). On T2*-phase MRI contrast, they are identifiable by curvilinear hypointensity
along the edge of the lesion that corresponds with iron laden phagocytic cells observed on
histopathological specimens (Bagnato et al., 2011; Absinta et al., 2016; Dal-Bianco et al., 2017).
Here, we refer to them as paramagnetic rim lesions (PRLs).
When first observed on MRI, the rim of a PRL was only visible on scans from ultra-high-field
strength (7T) magnets (Hammond et al., 2008; Absinta et al., 2013; Bian et al., 2013; Mehta et
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al., 2013). Recently, PRLs have been shown to be identifiable on the more common high-field
strength (3T) MRI scans as well, albeit with lower inter- and intra-rater reliability (Absinta et al.,
2018). This development strengthens their viability as a target on clinical MRI protocols,
particularly because the sequences studied can be acquired with high spatial resolution in less
than 4 minutes (Sati et al., 2014a). Previous studies of PRLs have noted the geometric nature of
the rim and worked to identify the rim on the quantitative susceptibility mapping contrast as well
(Eskreis‐Winkler et al., 2015; Wisnieff et al., 2015; Stüber, Pitt and Wang, 2016).
Manual inspection of MS lesion for the presence of a paramagnetic rim is difficult, time
consuming, and prone to inter- and intra-rater variability. We propose an automated method for
identifying PRLs that would improve efficiency of study and facilitate translation of this biomarker
into larger research studies and clinical practice. One way to identify PRLs is through the
quantification of visual patterns that characterize these data. Radiomics is an emerging field of
research that encompasses the extraction of quantitative features from biomedical images that
may reflect underlying pathophysiology (Rizzo et al., 2018). Studies have shown that radiomic
features are often useful predictors of known hallmarks of disease (Coroller et al., 2016; Liu et al.,
2016; Bakas et al., 2017; Sweeney et al., 2021), although they have not been used extensively in
the MS literature. We use radiomic features along with a random forest classification model,
which can flexibly model high dimensional data, to identify PRLs. Our method is fully automated
and uses a T2*-phase volume with isometric voxels and high spatial resolution that is acquired in
a clinically feasible acquisition time at 3T (Sati et al., 2014a).

3.2. Materials and Methods
3.2.1. Study population:
We studied 20 subjects with MS who were scanned under an institutional review board–approved
natural history protocol at the National Institutes of Health (NIH), who were included in this study
due to the presence of visible PRLs in MR scans. Subjects’ age at the time of scanning ranged
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from 20 to 66 years, with a mean age of 45 years (sd = 12) (Table 3.1). Written informed consent
was obtained from all participants. Data from this study can be shared upon reasonable request
and completion of a Data Transfer Agreement with the National Institutes of Health.
Table 3.1: Demographics of Study Sample

Demographics
N
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Age (mean (SD))

45.5 (12.4)

Male (%)

8 (40)

Phenotype (%)
Primary progressive MS

3 (15)

Relapsing-remitting MS

12 (60)

Secondary progressive MS

5 (25)

Disease Duration (mean (SD))

15.1 (9.0)

EDSS (median (range))

2.5 (1.0–7.0)

Treatments (%)
Untreated

6 (30)

Glatiramer acetate

1 (5)

Interferon beta-1a

4 (20)

Dimethyl fumarate

6 (30)

Fingolimod

1 (5)

Natalizumab

1 (5)

Rituximab

1 (5)
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3.2.2. MR Imaging acquisition:
All subjects were imaged on a Siemens Magnetom Skyra (Siemens, Erlangen, Germany) 3T
scanner, using a body transmit coil and a 32-channel receive array coil, at the National Institutes
of Health in Bethesda, Maryland. Imaging acquisition included the following sequences:

•

a whole-brain 3D T2-weighted fluid-attenuated inversion recovery (FLAIR) sequence
(repetition time, TR = 4800 ms; echo time, TE = 354 ms; inversion time, TI = 1800
ms; flip angle, FA = 120°; acquisition time, TA = 6 minutes 30 seconds; 256 axial
slices; 1mm isometric voxel resolution),

•

a whole-brain 3D T1-weighted magnetization-prepared rapid gradient echo (T1)
sequence (TR = 7.8 ms; TE = 3 ms; FA = 18°; TA = 3 minutes 35 seconds; 256
sagittal slices; 1mm isometric voxel resolution), and

•

a 3D segmented echo-planar imaging (EPI) sequence with whole-brain coverage
providing T2* magnitude and phase contrasts (TR = 64 ms; TE = 35 ms; flip angle,
FA = 10°; TA = 5 minutes 46 seconds; 251 sagittal slices; 0.65mm isometric voxel
resolution).

Additional standard MRI sequences, including a postcontrast 3D T1-weighted MPRAGE
sequence for the identification of gadolinium-enhancing lesions, were also acquired but not
incorporated into the automated assessment of PRLs.

3.2.3. Manual paramagnetic rim lesion assessment:
Supratentorial non-gadolinium enhancing MS lesions were visually inspected for the presence of
a paramagnetic rim on T2* magnitude and unwrapped phase images by a neurologist with 14
years of experience in neuroimaging science (Absinta et al., 2013, 2018, 2019). Gadolinium
enhancing lesions were excluded from the analysis because the main focus of this paper was to
study chronic rim lesions. In Absinta et al. (2016) (Absinta et al., 2016), PRLs were found in 22
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out of 40 gadolinium enhancing lesions. Of these 22, 45% of the rims disappeared within 3
months after enhancement resolved. As previously described (Yao et al., 2012), we identify a
PRL when a hypointense signal on phase images is observed surrounding the periphery of the
lesion, while being either hyper- or isointense in its inner portion. PRLs were delineated on the
phase with a line through the center of the lesion along its longest axis on an axial slice.

3.2.4. Image preprocessing:
Phase images were unwrapped and filtered as previously described (Absinta et al., 2013). T1,
FLAIR, and phase images were preprocessed using the fslr R package (Muschelli et al., 2015),
an R wrapper for the FSL software(Smith et al., 2004; Jenkinson et al., 2012), further described
below. Images were visualized with ITK-SNAP (Yushkevich et al., 2006). The T2*-magnitude
contrast was not used in this method.
To preprocess our images, we first applied the N4 inhomogeneity correction algorithm to the T1,
FLAIR, and phase images (Tustison et al., 2010). We then rigidly registered both the T1 and the
FLAIR images to the T2*-phase image space, resampling to 0.65 mm isometric resolution and
using a mutual information cost function and sinc interpolation. When deciding on registration
parameters, we also considered using 9-parameter and 12-parameter registration but found that
registration with those degrees of freedom resulted in some failed cases with warped images. We
used multi-atlas skull stripping (MASS) to identify cerebral tissue in the images in T1 space
(Doshi et al., 2013). In two cases, MASS yielded poorly skull-stripped images based on visual
inspection. For those two cases, we instead used the FSL brain extraction tool for skull-stripping
(Jenkinson et al., 2012). As a final step, we performed WhiteStripe intensity normalization on the
otherwise preprocessed T1, FLAIR, and phase images (Shinohara et al., 2014).

3.2.4. Lesion labelling:
Our lesion labelling method relies on access to maps that represent voxel-wise probabilities of
being a lesion. We use the automatic lesion segmentation method MIMoSA for its ability to
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integrate multimodal information and to provide voxel-wise probability maps (Valcarcel et al.,
2018b). Manual lesion segmentation was conducted by a research assistant with 1 year of
experience, who was trained by a board-certified neurologist with extensive expertise in
neuroimmunology and MRI.
We trained the MIMoSA algorithm with manual segmentations as a gold standard and T1 and
FLAIR images as input. We implemented a leave-one-out cross-validation approach, where data
from all but one subject was used to train a MIMoSA model, and that model was subsequently
applied to the remaining subject. We repeated this for every subject in our cohort.
From each k-fold model, we extracted probability maps that contained voxel-wise probabilities of
being a white matter lesion. We then binarized these probability maps into lesion segmentation
maps via a subject-specific estimated optimal threshold that was identified out of a user-provided
range of possible thresholds and then chosen based on amount of overlap with a gold-standard
lesion segmentation as measured by a Sørensen-Dice coefficient (Valcarcel et al., 2020).
Because our lesion segmentation masks did not always cover the entire area of a lesion, we then
dilated the masks by one voxel in each direction to increase the likelihood of detecting the
paramagnetic rim signal, which occurs on the boundary of lesions. In order to then mitigate the
possibility that our dilation inadvertently resulted in the added inclusion of CSF or gray matter, we
used FSL FAST to segment CSF and gray matter and masked those out of the voxels newly
included through dilation (Zhang, Brady and Smith, 2000).
After lesion segmentation masks were obtained, we used the lesion probability maps as input to a
center detection method (Dworkin et al., 2018b) to identify distinct lesions based on the texture of
the lesion tissue. We then used a nearest-neighbor approach to classify the remainder of the
lesion segmentation map into those identified lesions (Figure 1). At this point, we assigned PRL
status to the identified lesions based on the presence of any overlap with the manual PRL labels
described previously.

26

Due to failures in the lesion labelling process, a subset of abnormalities automatically identified by
our method might, to a manual rater, be considered clusters of confluent lesions. Because we did
not have access to manual segmentations of distinct lesions, we instead relied on a combination
of our lesion labelling method and connected components analysis to label lesions as confluent.
Specifically, if connected components identified one cluster where our lesion labelling method
identified more than one lesion, we labelled the constituent lesions as confluent.

3.2.5. Feature extraction:
With the lesions identified by our automatic pipeline, we conducted a radiomic image analysis to
characterize each lesion with intensity-based statistics on the phase contrast (Kolossváry et al.,
2017). These include 44 features that summarize the intensities in an individual lesion in 3
general ways: by describing the average and spread of the intensities, by describing the shape of
the distribution of intensities, and by describing the diversity of intensities(Kolossváry et al.,
$

2017). For example, features like the mean, defined as ∑ '$ & , and interquartile range, defined
as ()* &+,% − &
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, are included in the first group, where & represents intensity value at voxel .
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Features like variance, defined as ∑ '$/& − 01(
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are included in the second group, and features like energy, defined as ∑ '$ & , uniformity, defined
as ∑ '$ ? &

, and entropy, defined as ∑ '$ −? & log ? & , are included in the third group. A

full list and detailed equations for each of the first-order radiomic features can be found in the
supplemental material of Kolossváry et al. (2017) (Kolossváry et al., 2017).

3.2.6. Prediction model:
The radiomic features were used as candidate predictors in our subsequent prediction modelling
for classification of PRL lesions. Class labels for each lesion were previously assigned during the
lesion labelling step. We split our dataset into a training set and test set by subject, randomly
assigning lesions from 16 subjects into the training set and lesions from the remaining 4 subjects
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into the test set. Both sets were examined to ensure that at least 100 lesions were present in
each group.
Because PRLs were of a minority class with a prevalence of approximately 12%, we used
Synthetic Minority Oversampling TEchnique (SMOTE) to balance our data (Chawla et al., 2002).
With SMOTE, we oversampled the PRLs by the reciprocal of the percentage of PRLs present in
the dataset and we did not undersample the majority class. We then trained a random forest
classifier with 10-fold cross-validation using the R package caret (Kuhn, 2008; Wright and Ziegler,
2017). We summarized performance results using an optimal threshold calculated based on
Youden’s J statistic, which maximizes the sum of sensitivity and specificity (Youden, 1950). We
also derived empirical confidence intervals for those measurements by randomly reassigning the
training and test set and repeating the above process 1000 times. We assessed variable
importance in the random forest as the percent increase in mean-squared error for a model with
the variable over a model with a permuted version of that variable, scaled for comparability
across variables.

3.2.7. Post-hoc analyses:
An additional board-certified neurologist (MS) with extensive expertise in neuroimmunology and
MRI, who was not involved in the generation of the manual PRL labels, examined each
misclassified lesion. We rated lesions on a 5-point scale, where 1 indicated definitely not a PRL, 2
indicated probably not a PRL, 3 indicated uncertain, 4 indicated probably a PRL, and 5 indicated
definitely a PRL. Some lesions were automatically labelled as one lesion but were actually a
confluence of lesions (Figure 1). We assigned manual ratings to these confluent clusters based
on the presence of at least one PRL. We additionally assessed APRL’s performance only for
lesions that were not part of a confluent cluster.
Because it is known that the sizes of PRLs tend to be larger than non-PRLs, we extracted lesion
size for use as a potential feature in our prediction model, measured as the number of voxels in a
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given lesion.

Figure 3.1: A visualization of the steps of the method for five different lesions. Each column corresponds to
a different part of the method, and each row corresponds to a different lesion of interest. In columns 5 and 6,
the different colors represent different lesions, where the colors are arbitrarily assigned. In the last column,
lesions classified as PRLs are visualized as green, and lesions classified as not PRLs are visualized as red.
Subfigure A shows a lesion that was both manually identified as a PRL and classified as a PRL, i.e. a true
positive. Subfigure B shows a lesion that was manually identified as not a PRL but classified as a PRL, i.e. a
false positive. Correspondingly, subfigure C shows a false negative lesion, and subfigure D shows a true
negative lesion. Subfigure E shows a lesion that was automatically labelled as a single lesion but is actually
a confluence of lesions.

3.3. Results
The final dataset included a total of 951 lesions in 20 subjects identified by our automated lesion
labelling method, 113 (12%) of which we found to be PRLs by overlap with the manual
annotation. The average number of lesions per subject was 47.6 (sd = 15.9), and the average
number of automatically identified PRLs per subject was 5.7 (sd = 2.9). The number of identified
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PRLs by our method was highly correlated with the gold standard count of PRLs, r = 0.86 (95%
CI [0.68, 0.94]) (Figure 3.2).

Figure 3.2: Subfigure A shows the manually identified count of PRLs against the number of PRLs estimated
via our lesion identification method, r = 0.86 (0.68, 0.94). Subfigure B shows the ROC curve after
classification, AUC = 0.82 (0.74, 0.92).

We trained a random forest classification model using PRL status from the lesion labelling
method as the label. In the iteration that we used to derive performance measures, there were
753 lesions in the training set, 81 of which were PRLs, and 198 lesions in the testing set, 47 of
which were PRLs. Using only the undiscretized radiomic features, we were able to classify
lesions with an AUC of 0.82 (95% CI [0.74, 0.92]). Using 0.502 as a probability threshold, the
optimal threshold as determined by Youden’s J, 135 lesions were accurately classified as not
PRL, 31 lesions were false positives, 8 were false negatives, and 24 were classified correctly as
PRL (Table 3.2). A breakdown of the classification results for the test set lesions by subject is
provided in Table 3.2, in which we see that the distribution of classification results is not very
different between patients.

Table 3.2: Summary of Classification Performance Measures. The table summarizes the performance
measures we observed for the classification of PRLs, where counts in parentheses are counts excluding
confluent lesions. 95% confidence intervals are provided for performance measures where available.
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Contingency Table (Excluding Confluent Lesions)
Reference
Prediction
Rim Negative

Rim Positive

Rim Negative

135 (47)

8 (0)

Rim Positive

31 (19)

24 (6)

Testing Set Lesion Classification Count by Subject (Excluding Confluent Lesions)
Subject

True Negative

False Negative

False Positive

True Positive

1

65 (24)

4 (0)

10 (4)

4 (1)

5

13 (4)

1 (0)

8 (2)

7 (0)

8

25 (7)

0 (0)

4 (3)

5 (0)

16

32 (12)

3 (0)

9 (10)

8 (5)

Performance Measures

With Confluent Lesions (95% CI)

Without Confluent Lesions

AUC

0.82 (0.74, 0.92)

0.88

Accuracy

0.8 (0.59, 0.91)

0.74

Positive Predictive Value

0.44 (0.17, 0.55)

0.24

Negative Predictive Value

0.94 (0.93, 1)

1

False Positive Rate

0.19 (0.07, 0.46)

0.29

False Negative Rate

0.25 (0, 0.37)

0

Sensitivity

0.75 (0.63, 1)

1

Specificity

0.81 (0.54, 0.93)

0.71

We also examined the results of the method for lesions that were not part of a confluent cluster. A
total of 72 lesions in the test set were not confluent, and were able to be classified with an AUC of
0.88. Using 0.086 as the probability threshold, the optimal threshold for this subset of lesions as
determined by Youden’s J statistic, 47 lesions were accurately classified as not PRL, 19 were
false positive, 0 were false negative, and 6 were accurately classified as PRL (Table 3.2).
Additional performance measures are provided in Table 3.2. Because we examined confluent
lesions as part of a post-hoc analysis, we did not derive confidence intervals for these
performance measures.
A visualization of lesions that were true positive, false positive, false negative, and true negative
respectively is provided in Figure 1. From subfigure B, where we see the method illustrated for a
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lesion that was falsely identified as a PRL, we can see that hypointensities can manifest around a
lesion even when they cannot be rated as a rim. Conversely, from subfigure C, which shows a
lesion that was falsely identified as not a PRL, we see that despite the presence of
hypointensities that are visible to the eye, certain PRLs may not display a signal strong enough to
be captured by radiomic features.
The random forest identified uniformity, entropy, and energy as the most important radiomic
features for classifying lesions, which are all features that aim to describe the diversity of the data
points (Figure 3.3). Other radiomic features that were important were mode, kurtosis, and skew.
Entropy and uniformity were both higher in lesions that were not PRLs, and energy was higher in
PRLs. In a model including lesion size as an additional predictor, the random forest identified
lesion size as the most important feature, with PRLs expressing larger sizes than lesions that
were not PRLs, predicting PRL status with an AUC of 0.81. A model using textural features
classified lesions with an AUC of 0.72.
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Figure 3.3: The variables identified as the most important by APRL for determining the presence of PRLs
were uniformity, entropy, and energy. Here, we measure variable importance as the percent increase in
mean squared error for the model with the variable over the model with a permuted version of that variable,
scaled for comparability across variables. Boxplots of uniformity, entropy, energy, and lesion size on the
lesions from the test set show that PRLs and non-PRLs seem to differ on those measures, supporting the
theory that they are important for distinguishing the two kinds of lesions.
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A second expert manually rated the 39 lesions that were misclassified by the model. The rater
deemed that 1 lesion included too much artifact to assess PRL status, and 25 lesions were
confluent. Of the lesions not part of a confluent cluster, 9 were false positive and 5 were false
negative. Of those 9 false positive lesions, 4 were rated as definitely a PRL, 2 were rated as
uncertain, 2 were rated as probably not a PRL, and 1 was rated as definitely not a PRL. For the 5
false negative lesions that were not confluent, 1 was rated as definitely a PRL, 2 were rated as
probably a PRL, 1 was rated as uncertain, and 1 was rated as probably not a PRL.
As for confluent clusters, 22 were false positives and 3 were false negatives. These were rated
according to the presence of at least one PRL in each confluent cluster. Of the 22 false positive
lesions, 11 were rated as definitely a PRL, 5 were rated as probably a PRL, 1 was rated as
uncertain, 3 were rated as probably not a PRL, and 2 were rated as definitely not a PRL. All 3 of
the false negative lesions were rated as definitely a PRL. We note that the confluence defined
here was a judgement made by the manual rater. This differs from but complements the
confluence definition employed for the primary test set analysis, which was the definition based
on the automated analysis used to derive the performance measures reported in Table 3.2.

3.4. Discussion
Preliminary studies have shown that the existence of a paramagnetic rim around an MS lesion is
an important biomarker with potential clinical implications: indicative of chronic inflammation,
associated with heightened disability, and resistant to current disease-modifying treatments
(Absinta et al., 2019). However, paramagnetic rims are time-consuming to identify manually, even
by highly trained experts (Absinta et al., 2018). In this paper, we developed APRL, a fully
automatic method for detecting paramagnetic rim lesions on a 3T MRI using a submillimeter
isometric, clinically feasible, segmented-EPI sequence (Sati et al., 2014a; Absinta et al., 2018).
Automation of PRL identification that relies on objective assessment would aid larger scaled

34

studies assessing this promising imaging biomarker in MS. Other automated approaches have
also been explored (Barquero et al., 2020).
APRL relies on radiomics for automated PRL identification and classification. Radiomic features
have not previously been used to classify PRLs. The radiomic features that were the most
important in this context aimed to measure the variability of intensity within a lesion (entropy and
uniformity) or quantify the magnitudes of the intensities themselves (energy).
Energy measures the magnitude of intensities within a lesion. On the phase image used in this
study, PRLs manifested with higher energy because hypointensities represented more extreme
negative values instead of values closer to 0, with more extreme hypointensities resulting in more
extreme energy values.
Both entropy and uniformity are measures based on the probability of observing a particular
intensity within a lesion. Because we did not bin the voxel intensities, the number of distinct
intensities observed was large, so the probability of observing a particular intensity was fairly low.
This was reflected in the observed range of uniformity in this study. Uniformity is a direct measure
of homogeneity of the intensities within a lesion. We expected uniformity to be lower for PRLs due
to the presence of both intensities representing normal appearing tissue and hypointensities from
the paramagnetic rim. Lesions that were not PRLs did not appear with any distinct signature on a
phase image, leading to a higher uniformity. In addition, the impact of the size of a region of
interest on radiomic features in MS lesions has not been well studied and warrants further
investigation.
Entropy takes the probability of observing a particular intensity within a lesion and transforms it to
reflect the amount of observed variation. Because of the aforementioned lack of binning, here,
entropy more accurately reflected lesion size in that given our more homogenous set of
probabilities, a smaller probability of observing a given intensity resulted in a smaller measure of
entropy. Larger lesions yielded a smaller probability of observing a given intensity. In this dataset,
PRLs tended to have smaller values of entropy, possibly reflecting a larger size, which has been
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noted in previous studies of PRLs as well (Dal-Bianco et al., 2017). When we included lesion
size in our classification model, we found that lesion size was an important predictor of PRL
status in addition to uniformity, entropy, and energy, suggesting that these four measures provide
potentially similar but nevertheless complementary forms of information for classifying PRLs.
Many of the lesions that the model misclassified were confluent lesions that were labelled as a
single lesion. According to our automated assessment of confluence, the percentage of confluent
lesions among correctly classified lesions was 33%, while the percentage of confluent lesions
among incorrectly classified lesions was 49%, suggesting that confluence negatively influences
the model’s ability to classify PRLs. According to our expert rater’s visual assessment of
confluence, nearly 65% of misclassified lesions were confluent. Of these, 88% were false
positives, potentially reflective of heterogeneity in intensity that is more present for confluent
lesions but also in lesions with a rim signal. Confluent lesions also tend to be larger, similar to
PRLs, which may have also contributed to the misclassification.
We provide an example of one of these confluent lesions in Figure 1, Subfigure E. In this lesion,
although one of the encompassed lesions contains a clear rim signal, the larger of the two does
not. Because the majority of the voxels included in the confluent lesion belong to the
encompassed one without a rim signal, the first-order radiomic features extracted from this
confluent lesion reflected that signal.
We dilated our lesion segmentation map to increase the likelihood that a rim signal would be
included in a lesion label. In order to mitigate the impact of inclusion of ventricular and cortical
phase-hypointensities, we masked out cerebrospinal spinal fluid and gray matter from the
dilations, but this dilation could have nevertheless resulted in the inclusion of non-lesional tissue
that may have affected the calculation of radiomic features.
These issues could be addressed by taking a more nuanced approach to modelling the
probability of having a rim. Here, we treated the identification of PRLs as a binary classification
problem, invoking a random forest to predict if a given lesion was a PRL. However, the
36

identification of PRLs can be difficult because of the myriad of factors that drive the clarity and
strength of a rim signature, some of which are technical and some of which reflect biological
processes. As noted in Figure 1, while some lesions exhibit a rim unequivocally, other lesions
exhibit a more equivocal signature. This renders the task of identifying PRL lesions difficult, both
for manual raters and automated classifiers. In fact, previous research has shown that intra- and
interrater reliability for paramagnetic rim evaluation are substantial but not perfect, with a Cohen @
of 0.77 and 0.71 respectively (Absinta et al., 2018). A future approach could treat the presence of
a rim as a continuous measure instead of a binary classification, where middling levels of this
theoretical measure could represent both uncertainty about a lesion’s classification and different
stages of PRL progression. This would likely more accurately reflect underlying biological
processes as well, as the amount of iron-containing phagocytes at the edge of a lesion can vary
across lesions (Dal-Bianco et al., 2017).

3.4.1. Limitations:
A major limitation to current assessments of paramagnetic rims is that no international consensus
exists on criteria for determining this imaging signature. This limitation may hinder the application
of the proposed methodology to new studies in which differing definitions of paramagnetic rims
may be desired based on local practices. While signal-to-noise ratio is higher on a 7T MR image,
allowing for higher inter- and intra-rater reliability, they remain low across contrast types on 3T
(Absinta et al., 2018). However, APRL relies on techniques that perform well on 3T images, so
extensions to 7T would require additional validation.
This study may be improved by the collection of additional data containing delineations of rim
signal locations. Increasing the sample size may allow for a more accurate reflection of the
imaging signature associated with PRLs within the feature space, and a more specific delineation
of the rim signal may improve APRL’s ability to differentiate between hypointensity due to the
presence of a rim and hypointensity due to noise or features like the central vein sign. In the
current study, we did not explicitly assess for the presence of a central vein sign in each of the
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automatically identified lesions. Because the central vein sign also presents as hypointensity
within a lesion on T2*-phase, a central vein sign might impact the calculation of first-order
radiomic features. Textural features, which quantify the spatial relationship between voxel
intensities, characterized PRLs less accurately than first-order features. Future studies may
explore more direct methods for quantifying the central vein to disentangle the rim signal and the
central vein sign. In addition, all the patients for this analysis had at least one PRL. Given recent
histology work (Gillen et al., 2021), we do not suspect that patient without PRL lesions would
have different radiomic signatures in their non-PRL lesions from patients with PRL lesions, but
further work is warranted to investigate this.
Additionally, in the current study, we did not explicitly consider gadolinium-enhancement in our
automated identification of PRLs. Gadolinium-enhancing lesions were specifically left out of the
manual assessment in an effort to specifically study chronic rim lesions, whose presence has
previously been shown to be associated with poor prognostic factors (Absinta et al., 2019).
Paramagnetic rims in gadolinium-enhancing lesions fade within 3 months in a high percentage of
cases (Absinta et al., 2016) and may exhibit features different from chronic rim lesions on imaging
due to edema and tissue architecture, though this was not explicitly studied in this analysis.

3.5. Conclusion
This study introduces a fully automated method, APRL, for the identification and classification of
paramagnetic rim lesions relying solely on 3T MR images, which are commonly available in a
clinical setting. Automation of this process is important for the continued development of the
scientific community’s knowledge around these lesions and their implications for disease burden.
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CHAPTER 4:
A NOVEL COORDINATE SYSTEM FOR MULTIPLE SCLEROSIS LESION
EVALUATION ON MAGNETIC RESONANCE IMAGING

4.1. Introduction
Multiple sclerosis (MS) is a chronic, inflammatory demyelinating, and neurodegenerative disease
of the central nervous system with no known cure. The symptoms and clinical trajectories of MS
can vary widely, making diagnosis and prognosis difficult to determine. Around 20 to 30 percent
of patients diagnosed with MS are actually misdiagnosed, and around 30 percent of these
misdiagnosed patients incurred unnecessary morbidity due to their misdiagnosis (Solomon et al.,
2016; Yamout et al., 2017; Kaisey et al., 2019). The McDonald criteria are the primary method of
diagnosing MS, incorporating both clinical and imaging criteria, though misapplication of the
McDonald criteria through overinterpretation of imaging results has heavily contributed to current
misdiagnosis rates (Solomon, Klein and Bourdette, 2012; Thompson et al., 2018). The
prevalence of misdiagnosis has motivated the study of imaging biomarkers that may hold
improved diagnostic value.
Some biomarkers that have demonstrated potential in this space are specific to susceptibilityweighted imaging: in particular, the central vein sign, prominent on FLAIR* images, and the
paramagnetic rim signal, visible on derivatives of susceptibility-weighted imaging, have been
under study in recent years as potential diagnostic biomarkers (Sati et al., 2016; Solomon et al.,
2018; Absinta et al., 2019; Sinnecker et al., 2019; Maggi et al., 2020b). Automated methods for
both have been developed, and clinically relevant thresholds have been analyzed (Dworkin et al.,
2018c; Maggi et al., 2020a; Barquero et al., 2020; Lou et al., 2021b; Ontaneda et al., 2021). The
diagnostic value of both combined has also been shown to be high (Clarke et al., 2020). MS
lesions are also thought to be shaped differently from lesions in patients with MS imaging mimics,
in part also due to the perivenular nature of MS lesions, which leads to inflammation that is
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thought to gradually stem outwards from the source vein (Sinnecker et al., 2012; Wuerfel et al.,
2012; Kilsdonk et al., 2014). Recent work has shown that 3-dimensional phenotyping of MS
lesions that allow for assessment of both shape and surface characteristics also reveals
differences in complexity of surface morphology and symmetry (Newton et al., 2017; Okuda et al.,
2020).
These lesional features all aim to quantify ways that MS lesions are different from lesions from
patients with an MS imaging mimic. In particular, the defining feature of the central vein sign is
the existence of a hypointense tubular structure that appears at or near the center of a lesion.
The defining feature of a paramagnetic rim signal is that it appears as a distinct signal at the
lesion border. Lesion shapes rely on well-defined lesional boundaries that accurately reflect
measures such as complex surface morphology and elongation. For each of these novel imaging
biomarkers, a key characteristic is the specificity of both intensity and spatial distribution in the
lesion. We propose a novel coordinate system for MS lesions that incorporates both spatial and
voxel-wise intensity information in each lesion which can aid in discerning known diagnostic and
prognostic MRI biomarkers, such as the central vein sign and the paramagnetic rim signal.
We borrow ideas from the human brain mapping space and functional data analysis to motivate
the idea that building a common template for MS lesions through iterative registration can be a
powerful framework for analyzing lesions (Avants et al., 2010, 2011). We propose a novel
coordinate system that incorporates both spatial and voxel-wise intensity information in each
lesion which could aid in discerning known diagnostic and prognostic MRI biomarkers, such as
the central vein sign and the paramagnetic rim signal. Leveraging the central vein sign and
estimated lesion boundaries, particularly relevant in the context of confluent clusters of lesions,
we represent a given lesion in spherical coordinate space and then assess the added value of
these features by examining association with clinical outcomes.
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4.2. Materials and Methods
4.2.1. Data
The data used for this study comes from 68 people presenting for suspicion of multiple sclerosis
who were imaged at the University of Vermont on a Phillips scanner. 23 of these patients were
eventually diagnosed with MS while the remaining 45 were diagnosed with alternate disorders. 3D 3Tesla magnetic resonance images with T1, T2-FLAIR, and T2* echo planar images were collected for all
patients. Whole-brain 3D T2-FLAIR, T1, and T2*-EPI (Sati et al., 2014b) volumes were acquired in a 3T
Philips (dStream) MRI scanner. FLAIR and T1 volumes were obtained with 1-mm resolution, and T2*-EPI
volumes were obtained with 0.55-mm isotropic resolution.

4.2.2. Image Processing
All images were bias corrected using N4 bias correction. T1 and T2*-magnitude images were
skull-stripped using FSL BET (Jenkinson et al., 2012), the T1 was rigidly registered to the FLAIR
image with windowed sinc interpolation, and these were both then also rigidly registered to T2*magnitude space. We also derived a vesselness map using a Frangi filter (Frangi et al., 1998;
Dworkin et al., 2018c). In order to get our centroids, we first intensity-normalize our T1 and FLAIR
images using WhiteStripe (Shinohara et al., 2014) and then feed those into a pre-trained MIMoSA
model with a 0.2 probability threshold (Valcarcel et al., 2018a). We then find the lesion centers
using a technique proposed by Dworkin et al (Dworkin et al., 2018a) that relies on the texture of
the lesion probability map to quantify areas with high probability of being a lesion. Periventricular
centroids were then removed, and subsequently, all maps (i.e. T1, FLAIR, mimosa probability
map, lesion segmentation map, and lesion centroid map) were registered to T2*-magnitude
space.
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4.2.3. Lesion Patch Generation
To create our template lesion, we first create image patches for each of our lesions on each of
our subjects by masking out the lesion itself and then padding the image with 5 voxels on each
side of each axis. For every lesion, we create patches of the FLAIR, EPI, and vesselness maps.
We then create distance-to-boundary maps for each lesion and multiply that by the Frangi map
for that lesion to create what we call a “coherence” map. We then run connected components on
the map in order to identify a vein and determine each lesion to have the central vein sign if the
largest component has more than 16 voxels. We then take the map of the connected components
of the coherence map, now a binary mask, and rigidly register those together in hopes of aligning
the most clear vein-like signal within a lesion. We apply these registrations to the magnitude and
flair images and then start the template construction process.

4.2.4. Template Creation
For template construction, we utilize a two-stage process for constructing an all-subject template:
first, we construct subject-specific templates using a multimodal template construction pipeline as
described by Avants (Avants et al., 2011), and then we linearly register those subject-specific
templates to one of the subject-specific templates, chosen manually for the presence of a distinct
vein.
For the construction of subject-specific lesions, we use only the lesions with a strong vein-like
signal. We first create coherence maps that enhance the strongest central tube-like signal in each
lesion by binarizing the largest connected component on a given lesion’s coherence map. We
then rigidly register these enhanced coherence maps together and apply estimated registrations
to the FLAIR and EPI lesions. We then take the rigidly registered FLAIR and EPI lesions and use
multimodal template construction in the ANTs environment (Avants et al., 2011). We use a
gradient step of 0.15, 10 iterations, and both a linear and a nonlinear registration, summarized
using the mean of normalized intensities, with equal weighting on the FLAIR and EPI images.
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Figure 4.1: Example images of MS lesions, processed and unprocessed. In subfigure A, we see an
example of an MS lesion in native space. The blue segmentation indicates the automatically derived
centroid mask. The Frangi vesselness filter and coherence map highlight the central vein in the center of the
lesion. In subfigure B, we see 3 example lesions from the same subject. Our pre-template construction
registration pipeline consists of initial within-subject rigid registration of coherence maps, followed by
application of the estimated registration to EPI and FLAIR images. This process allows for template
construction to align the vein signal as best as possible.

Once the subject-specific templates are constructed, we then take the templates from patients
who were diagnosed with MS and linearly register those subject-specific templates to a chosen
subject template, smooth the registered subject-specific templates and then average them to form
our all-subject template. For patients who were diagnosed with an alternate disorder, we use
“similarity” registration (i.e. rotation, translation, and scaling) in order to register their subjectspecific templates to the all-subject template and save that registration.
To then register all the lesions into all-subject template space, we nonlinearly (SyN) register them
to their subject-specific template, and then use that and the transformation estimated by the
registration of the subject-specific template to the all-subject template to register the EPI to all43

subject template space (Avants et al., 2008). We use those transformations estimated by EPI-tosubject-specific template registration and subject-specific-to-all-subject-template space to also
register our coherence maps, estimated in native space, to all-subject-template space.

4.2.5. Statistical Modelling
To identify axes of variation among lesions, we vectorize all lesion patches registered to template
space and then perform PCA on our matrix of vectorized lesions, for which the intensities at each
voxel location across lesions are centered but not scaled. We then extract the scores of each of
the principal components (PCs), and analyze those with respect to the difference between lesions
from MS patients and lesions from patients with an alternate disorder. We measure the degree to
which that difference exists by performing a two-sided t-test that we Bonferroni-correct by the
number of lesions in our study.
For the PCs that we identify as containing information that significantly differentiates MS and nonMS lesions, we then model the association between those PC scores and diagnosis using the
following linear mixed effects model:
A = BC + DE + F
where A is the PC score under study, C is a vector containing an intercept term and a term for MS
diagnosis, and E represents a random intercept on subject. We limit our study of PCs to the first
10, as we believe that interpretability is difficult for PCs that capture a small amount of variability
within the original dataset.
We evaluate the significance of the association between diagnosis and PC score by using
Satterthwaite’s degrees of freedom method (Satterthwaite, 1946; Kuznetsova, Brockhoff and
Christensen, 2017). We also evaluate the diagnostic accuracy of those PCs by extracting a
number of summary statistics and using them in a random forest model to model diagnosis. The
summary statistics we calculate are as follows: maximum, minimum, median, mean, variance,
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interquartile range, skewness, and kurtosis. We cross-validate these results using leave-one-out
cross validation.
In order to mitigate overfitting, we perform 5-fold cross validation with folds based on subject. For
each fold, we first take our patients in the training set of the fold, perform PCA on the lesions from
those patients, as outlined above, find the PC with scores that most significantly differentiate MS
and non-MS lesions, and use statistics of that PC summarized by subject to model diagnosis. As
an alternative feature set, we also extract the medians of all PCs that significantly differentiated
MS and non-MS lesions and use those features in a random forest to model diagnosis. Diagnosis
was modeled using, separately, a generalized linear model and a random forest. For the patients
in the test set of the fold, we map the lesions from those patients into the PC space estimated by
the training set, extract the PC identified by the training set as most significantly differentiating MS
and non-MS patients, and predict diagnosis using summary statistics for that PC.

4.3. Results
After preprocessing, we had 3114 lesions from 63 patients under analysis, 22 of whom were
diagnosed with MS and 41 of whom were diagnosed with an alternate disorder. There was an
average of 49 lesions from each patient (Range: 8—200); among MS patients, this was an
average of 68 lesions per patient (Range: 14—200), and among non-MS patients, this was an
average of 39 lesions per patient (Range: 8—180). For subject-specific template construction, for
which we only utilized a subset of our original set of lesions, we used an average of 7 lesions per
patient.
For our study-wide template, we used a total of 252 lesions from 22 patients with MS, with an
average of 11 lesions per patient, all of which were selected because of the existence of a strong
vein signal in the center of the lesion. Our final study-wide template lesion was 23 voxels by 46
voxels by 29 voxels large, for a total of 30682 voxels.
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Figure 4.2: Subfigure A: The all-subject template contains hypointensity in the center of the lesion that
reflects hypointense pattern expected for a vein-like signal, circled in red. Subfigure B: The subject-specific
template from an MS patient has a more prominent hypointensity in the center of the lesion than the
subject-specific template from a non-MS patient. Lesions from MS patient registered to template space
maintain visible vein-like pattern but lesions from non-MS patient do not show this pattern.

To analyze our resultant lesions registered to template space, both MS and non-MS, we perform
PCA on a vectorized version of the images in the form of a matrix of 3114 lesions by 30682
voxels. When we then analyze which principal component scores significantly differentiate MS
and non-MS lesions after Bonferroni correction, we see that 7 of our principal components
significantly differentiated MS and non-MS lesions. P-values assessing the significance of the
difference between MS and non-MS lesions by PC score are reported in Table 4.1 below
alongside inference derived from a mixed-effects model examining the association between PC
score and diagnosis while accounting for subject-level variation.
Table 4.1: Inference for PC Scores and MS Diagnosis. Principal components with scores that significantly
differentiated lesions from MS patients and lesions from non-MS patients are listed alongside the p-value for
a test of significant differences. We also report results for a test of significance for the association between
MS diagnosis and PC score within a mixed-effects model accounting for random variation on the subject
level.
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Principal
Component

Association
between MS
Diagnosis and PC
Score: P-Value

Association between MS
Diagnosis and PC Score
accounting for subjectlevel variation: P-value

PC2

2.29E-25

0.0558

PC3

1.35E-06

0.719

PC4

9.63E-23

0.026

PC8

5.43E-06

0.0452

PC9

8.57E-08

0.345

PC10

2.14E-31

0.00306

The summary statistics of just PCs that are significantly associated with diagnosis after
accounting for subject-level variation, when modeled univariately in a generalized linear model,
yield AUCs of 0.83 and 0.76 for PC4 and PC10 respectively. If we cross-validate the predictions
using a leave-one-out-cross-validation scheme across patients, we see AUCs of 0.66, 0.58, and
0.60. When we take the medians of each PC that significantly differentiated MS and non-MS
lesions across subject and use those as features in a generalized linear model, we see an insample AUC of 0.87 and a leave-one-out-cross-validated AUC of 0.78.
After cross-validating the whole analysis pipeline, if we do an analogous analysis by taking the
medians of all significant (Bonferroni-corrected) PCs and modeling diagnosis, we see AUCs of
0.54 and 0.57 for our GLM and random forest respectively. If we model diagnosis with summary
statistics of just the PC that most significantly differentiated MS and non-MS lesions within that
fold, we see AUCs of 0.64 and 0.59 for our GLM and random forest respectively. The most
significant PC per fold and a list of the significant PCs per fold are listed in Table 4.2.
Table 4.2: List of Significant Principal Components per Cross-validation Fold. Most significant PCs for
each fold are highlighted.
Fold
1
2
3
4
5

PC2 (2.14E-15)
PC2 (1.03E-19)
PC2 (7.75E-13)
PC2 (4.85E-33)
PC2 (2.04E-27)

PC3 (1.30E-11)
PC3 (2.68E-16)
PC3 (1.45E-10)
PC4 (4.71E-17)
PC4 (1.70E-22)

PC4 (1.84E-25) PC6 (7.76E-07)
PC4 (1.49E-19) PC8 (7.75E-26)
PC4 (4.17E-09) PC7 (2.72E-15)
PC5 (6.97E-08) PC8 (2.46E-11)
PC10 (1.84E-08) PC11 (6.16E-42)

Significant PCs Per Fold
PC10 (6.82E-26) PC12 (3.68E-07) PC19 (3.78E-09) PC52 (7.65E-06)
PC11 (4.20E-10) PC19 (1.09E-05) PC31 (6.17E-06)
PC8 (3.84E-11)
PC9 (5.97E-22)
PC21 (4.92E-13) PC36 (8.83E-07) PC107 (1.94E-05)
PC11 (1.57E-16) PC2477 (1.79E-05)
PC30 (6.56E-07) PC2337 (6.90E-07)
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Figure 4.3: Voxel-wise loadings for PC1, PC4, and PC10. The hyperintense voxels are voxels with high
loadings for a given PC, and hypointense voxels are voxels with low loadings for a given PC. The loadings
for these PCs seem to suggest that the in fact the largest amount of variation, as encapsulated by the first
PC, occurs in a ring around the center of a lesion. This may be capturing residual differences in lesion size.
PC4 and PC10 are each PCs that significantly differentiated MS and non-MS lesions, both with and without
accounting for subject-level variability. PC4 seems to capture variability primarily occurring in one tubular
direction and PC10 seems to capture variability occurring around the edge of lesions.

4.4. Discussion
We develop a novel morphological coordinate system for quantifying lesion damage and repair
that allows for simultaneous assessment of spatiality and intensity to address between-lesion
heterogeneity. Downstream analysis of MS and non-MS lesions registered to the coordinate
system shows the ability of our proposed method to highlight differences between lesions from
patients with different diagnoses.
Subject-specific template lesions created for MS patients maintain hypointense signal in the
center of the lesion while subject-specific template lesions created for non-MS patients do not
show that pattern. Lesions from MS patients registered to template space maintain the central
vein signal and appear closely aligned with each other while lesions from non-MS patients do not.
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Principal components analysis reveals that the scores of 7 out of 3114 estimated principal
components significantly differentiate MS and non-MS lesions. Three of these principal
components additionally significantly differentiate MS and non-MS lesions after accounting for
subject-level variation in lesion presentation. The loadings of these three principal components
each highlight different spatial patterns in a lesion, one highlighting variation occurring primarily in
a line through the center of the lesion, one highlighting variation primarily occurring on the outer
edges of the lesion, and one highlighting variation occurring directly around a hypointense tubular
form in the center of the lesion. Cross-validation shows that PC scores are a reliable way to
identify directions of variation between lesions and that analysis of the PC that most strongly
differentiates MS and non-MS lesions can yield diagnostic value.
The primary limitation of this implementation of this method, comes from the fact that we rely on
automatic segmentations of lesion labels for this study. A template lesion is naturally going to be
highly reliant on accurate delineation of lesion boundaries, but manual segmentation of lesional
tissue and identification of distinct lesions with lesional tissue can be very time-consuming, as
many MS patients have multiple lesions that are often confluent. For this reason, we rely on
automatic methods both for identifying lesional tissue as well as identifying distinct lesions, but
automatic methods are prone to mislabeling and may lead to inaccurate delineations of lesional
boundaries. Mislabeling of lesional boundaries can lead to inconsistencies in our ability to
measure the paramagnetic rim signal, which is defined by its presence specifically on the edge of
an MS lesion, as well as morphological features such as elongation and complexity of surface
morphology, which rely on lesion boundaries to define shape and size.
To avoid mishaps stemming from inaccurate delineation of lesion boundaries, in this iteration of
this work, we focus our study to lesion centroids, defined as lesional tissue with the highest
probabilities of being a lesion. By focusing the scope of our work to lesion centroids, we eschew
the ability to incorporate the paramagnetic rim signal and lesion morphology into our assessment
of diagnosis, but we are able to refine our template creation pipeline to highlight the central vein
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sign and amplify signals in the centers of lesions that may contain diagnostic value. Future
iterations of this work may benefit from manual segmentation of distinct lesions that allow for
more accurate measurements of the paramagnetic rim signal and lesion morphology alongside
the central vein sign for a template lesion that truly encapsulates all of the imaging signals that
are known to contain diagnostic value.
As an adjacent point, we primarily focus our downstream analyses here to just the template lesion
created for the T2*-EPI contrast, but supplemental imaging contrasts may be incorporated for
identification of the paramagnetic rim signal, most easily detectable on T2*-phase or quantitative
susceptibility mapping contrast (QSM). Other imaging contrasts not incorporated in this work
have also recently been shown to potentially contain important, complementary information for
diagnosis (Fazekas et al., 1999; Thaler et al., 2015; Eskreis-Winkler et al., 2017; Zhang et al.,
2018; Jang et al., 2020). Our current work only incorporates the T2*-EPI and the FLAIR contrast
for template construction.
Further work may explore a more robust initial registration pipeline: even after highlighting just the
most central tube-like structure within a lesion, rigid registration does not completely align the
CVS within lesions. An additional registration step simply using rotation may improve alignment of
vein signals. Also, this study incorporated images from patients with a range of alternative
disorders, which may reduce the ability of diagnostic evaluation to accurately identify MS-specific
traits. Comparison to a single alternative disorder may improve measurements of diagnostic
value.
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CHAPTER 5:
DISCUSSION

The growth in accessibility of neuroimaging data has prompted an increased focus on the study
of imaging biomarkers. The development and evaluation of these novel indices of brain
phenomena are critical to maximizing the utility of these data. Improper usage and development
can lead to spurious conclusions and false promises.

5.1. Imaging biomarkers augment statistical power
In Chapter 2, we show that individualized machine-learning-based imaging biomarkers can be
useful tools for augmenting the power of clinical trial analysis when the necessary information is
available. This improvement can offer decreased sample size requirements for detecting a given
effect size, providing greater flexibility in resource utilization. The novelty of this method arises
from the incorporation of individualized predictions based on powerful predictive algorithms,
which can lend power to the detection of an average treatment effect due to targeting of the
individuals in a given clinical trial. As robust neuroimaging biomarkers derived via machine
learning models become more available, the historical datasets that can be analyzed with those
models grow in size. These changes are expected to strengthen the radiomic prediction models
like the ones used in this study.
Our incorporation of the radiomic predictor relies on the existence of previously developed
imaging biomarkers. For the purposes of this paper, we theorize that these models have been
trained on a historical cohort. Because the radiomic predictor has been trained on a historical
cohort, the models that we fit to analyze a current trial inherently incorporate information from
historical controls. We generate values of the radiomic predictor for the current sample using the
model that was developed with a previous cohort.

51

Reductions in sample size requirement depend upon the strength of the prediction model. In
Chapter 2, both imaging biomarkers considered were built using SVMs. Other machine learning
techniques such as deep convolutional neural networks may provide greater predictive power. In
addition, gains in power for the primary outcome will be associated with gains in power for
secondary outcomes only to the extent that predictions from the prediction model are associated
with the secondary outcomes. We demonstrate that when the necessary information is available,
imaging biomarkers can be a powerful tool, especially when evaluating therapies for rare
diseases such as GBM or heterogenous diseases with long and slow progressions that require
many years of patient follow-up such as AD.

5.2. Towards automated paramagnetic rim assessment
Preliminary studies have shown that the existence of a paramagnetic rim around an MS lesion is
an important biomarker with potential clinical implications. Previous studies have found that
paramagnetic rim lesions are (1) indicative of chronic inflammation, (2) associated with
heightened disability, and (3) resistant to current disease-modifying treatments. However,
paramagnetic rims are time-consuming to identify manually, even by highly trained experts. In
Chapter 3, we develop APRL, a fully automatic method for detecting paramagnetic rim lesions on
a 3T MRI using a submillimeter isometric, clinically feasible, segmented-EPI sequence.
Automation of PRL identification that relies on objective assessment can aid larger scaled studies
assessing this promising imaging biomarker in MS.
A major limitation to current assessments of paramagnetic rims is that no international consensus
exists on criteria for determining this imaging signature. This limitation may hinder the application
of the proposed methodology to new studies in which differing definitions of paramagnetic rims
may be desired based on local practices. The identification of PRLs can also be difficult because
of the myriad of factors that drive the clarity and strength of a rim signature, some of which are
technical and some of which reflect biological processes. This renders the task of identifying PRL
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lesions difficult, both for manual raters and automated classifiers. A future approach could treat
the presence of a rim as a continuous measure instead of a binary classification, where middling
levels of this theoretical measure could represent both uncertainty about a lesion’s classification
and different stages of PRL progression. This would likely more accurately reflect underlying
biological processes as well, as the number of iron-containing phagocytes at the edge of a lesion
can vary across lesions.

5.3. The template multiple sclerosis lesion
In Chapter 4, we develop a novel morphological coordinate system for quantifying lesion damage
and repair that allows for simultaneous assessment of spatiality and intensity to address
between-lesion heterogeneity. Downstream analysis of MS and non-MS lesions registered to the
coordinate system shows the ability of our proposed method to highlight differences in lesion
presentation between patients with different diagnoses. Lesions from MS patients registered to
template space maintain the central vein signal and appear closely aligned with each other while
lesions from non-MS patients do not. Principal components analysis of lesions in template space
reveals that the scores of 7 out of 3114 estimated principal components significantly differentiate
MS and non-MS lesions. Three of these principal components additionally significantly
differentiate MS and non-MS lesions after accounting for subject-level variation in lesion
presentation. The loadings of these three principal components each highlight different spatial
patterns in a lesion, one highlighting variation occurring primarily in a line through the center of
the lesion, one highlighting variation primarily occurring on the outer edges of the lesion, and one
highlighting variation occurring directly around a hypointense tubular form in the center of the
lesion.
To avoid misrepresentation of lesional signals stemming from inaccurate delineation of lesion
boundaries, we focus our study to lesion centroids, defined as lesional tissue with the highest
probabilities of being a lesion. By focusing the scope of our work to lesion centroids, we eschew
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the ability to incorporate the paramagnetic rim signal and lesion morphology into our assessment
of diagnosis, but we are able to refine our template creation pipeline to highlight the central vein
sign and amplify signals in the centers of lesions that may contain diagnostic value. Future
iterations of this work may benefit from manual segmentation of distinct lesions or statistical
methods for defining lesional boundaries that allow for more accurate measurements of the
paramagnetic rim signal and lesion morphology alongside the central vein sign for a template
lesion that truly encapsulates all of the imaging signals that are known to contain diagnostic
value.

5.4. Summary
In this dissertation, we propose novel methodology for quantifying signals in neuroimaging data
and developing methodologies for incorporating these signals into statistical analyses. Each of
our three projects centers a different “level” on the neuroimaging analysis pipeline. First, we think
about how best to take advantage of previously built, well-validated imaging biomarkers that may
have been built to predict one particular outcome and how best to utilize those models in a setting
that may not always directly study what the radiomic predictor was built to analyze. Next, we use
high-dimensional feature extraction and machine learning classification models to develop a
novel radiomic predictor that quantifies an imaging signal that has shown clinical promise. Finally,
we develop new methodology for measuring disease severity by focusing in on the relationships
between intensity and spatiality on a voxel-level scale. We show that orientation within a common
coordinate space may help to improve detection of prognostic and diagnostic lesional imaging
signals.
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